Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status, Published online: 14 May 2018; doi:10.1038/s41416-018-0086-x
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic statusPredictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer, Published online: 14 May 2018; doi:10.1038/s41416-018-0083-0
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancerTumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy, Published online: 14 May 2018; doi:10.1038/s41416-018-0088-8
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsyHealth-related quality of life after treatment for bladder cancer in England
Health-related quality of life after treatment for bladder cancer in England, Published online: 14 May 2018; doi:10.1038/s41416-018-0084-z
Health-related quality of life after treatment for bladder cancer in EnglandHeterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Heterogeneous <i>MYCN</i> amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study, Published online: 14 May 2018; doi:10.1038/s41416-018-0098-6
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudyEndothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover, Published online: 14 May 2018; doi:10.1038/s41416-018-0110-1
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnoverSafety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study, Published online: 14 May 2018; doi:10.1038/s41416-018-0100-3
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyTumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma, Published online: 14 May 2018; doi:10.1038/s41416-018-0093-y
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinomaAZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status, Published online: 14 May 2018; doi:10.1038/s41416-018-0086-x
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic statusPredictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer, Published online: 14 May 2018; doi:10.1038/s41416-018-0083-0
Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancerTumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy, Published online: 14 May 2018; doi:10.1038/s41416-018-0088-8
Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsyHealth-related quality of life after treatment for bladder cancer in England
Health-related quality of life after treatment for bladder cancer in England, Published online: 14 May 2018; doi:10.1038/s41416-018-0084-z
Health-related quality of life after treatment for bladder cancer in EnglandHeterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
Heterogeneous <i>MYCN</i> amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study, Published online: 14 May 2018; doi:10.1038/s41416-018-0098-6
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudyEndothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnover, Published online: 14 May 2018; doi:10.1038/s41416-018-0110-1
Endothelial Akt1 loss promotes prostate cancer metastasis via β-catenin-regulated tight-junction protein turnoverSafety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study, Published online: 14 May 2018; doi:10.1038/s41416-018-0100-3
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyTumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma, Published online: 14 May 2018; doi:10.1038/s41416-018-0093-y
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinomaOne of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports.
A retrospective database was used to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. MRI and symptom changes were recorded.
Thirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced worsening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. One patient achieved a partial response with improved symptoms.
No relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms.
One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports.
A retrospective database was used to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. MRI and symptom changes were recorded.
Thirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced worsening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. One patient achieved a partial response with improved symptoms.
No relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms.
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval.
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's tumor biomarker status, rather than on tumor histology. Here we discuss key issues and implications arising from the biomarker-based disease classification implied by this historic approval.
Apert syndrome is a rare genetic disease that presents a diagnostic dilemma because of its similarity with other craniosynostosis syndromes. Currently, there is paucity of reports about adult patients in Afric...
https://ift.tt/2rFAxjc
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
https://ift.tt/2KYKmBx
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
https://ift.tt/2GcbnxY
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
https://ift.tt/2jUt9gm
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
https://ift.tt/2GbLDSq
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
Author(s): Amr E. Abouleish, Stanley W. Stead
https://ift.tt/2jUt1xo
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
Author(s): Amanda J. Morris, Joseph A. Sanford, Edward J. Damrose, Samuel H. Wald, Bassam Kadry, Alex Macario
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
Author(s): DeLaine Schmitz, Matthew T. Popovich
Publication date: June 2018
Source:Anesthesiology Clinics, Volume 36, Issue 2
Author(s): Neil N. Shah, Thomas R. Vetter
Data regarding transsplenic portal venous access for diagnostic imaging and endovascular intervention in children are limited, possibly due to concerns regarding high bleeding risks and resultant underutilization.
To investigate the safety and utility of transsplenic splenoportography and portal venous interventions in children.
A retrospective review was performed of all pediatric patients undergoing percutaneous transsplenic portal venous access and intervention at two large tertiary pediatric institutions between January 2012 and April 2017 was performed. Parameters assessed included procedural indications, procedural and relevant prior imaging, technical details of the procedures, laboratory values and clinical follow-up.
Transsplenic portal venous access was achieved in all patients. Diagnostic transsplenic splenoportography was performed in 22 patients and was 100% successful at providing the desired anatomical and functional information. Four transsplenic portal venous interventions were performed with 100% success: meso-Rex shunt angioplasty, snare targeted transjugular intrahepatic portosystemic shunt (TIPS) creation through cavernous transformation, pharmacomechanical thrombectomy for acute thrombosis, and transplant portal vein angioplasty. Intraperitoneal bleeding occurred in 2/26 (7.7%) and one case required transfusion (3.8%). No cases of hemorrhage were observed when transsplenic access size was 4 Fr or smaller.
Transsplenic splenoportography in children is safe and effective when noninvasive imaging methods have yielded incomplete information. Additionally, a transsplenic approach has advantages for complex portal interventions. Bleeding risks are proportional to tract access size and may be mitigated by tract embolization.
Data regarding transsplenic portal venous access for diagnostic imaging and endovascular intervention in children are limited, possibly due to concerns regarding high bleeding risks and resultant underutilization.
To investigate the safety and utility of transsplenic splenoportography and portal venous interventions in children.
A retrospective review was performed of all pediatric patients undergoing percutaneous transsplenic portal venous access and intervention at two large tertiary pediatric institutions between January 2012 and April 2017 was performed. Parameters assessed included procedural indications, procedural and relevant prior imaging, technical details of the procedures, laboratory values and clinical follow-up.
Transsplenic portal venous access was achieved in all patients. Diagnostic transsplenic splenoportography was performed in 22 patients and was 100% successful at providing the desired anatomical and functional information. Four transsplenic portal venous interventions were performed with 100% success: meso-Rex shunt angioplasty, snare targeted transjugular intrahepatic portosystemic shunt (TIPS) creation through cavernous transformation, pharmacomechanical thrombectomy for acute thrombosis, and transplant portal vein angioplasty. Intraperitoneal bleeding occurred in 2/26 (7.7%) and one case required transfusion (3.8%). No cases of hemorrhage were observed when transsplenic access size was 4 Fr or smaller.
Transsplenic splenoportography in children is safe and effective when noninvasive imaging methods have yielded incomplete information. Additionally, a transsplenic approach has advantages for complex portal interventions. Bleeding risks are proportional to tract access size and may be mitigated by tract embolization.
The number of maxillofacial trauma (MFT) cases attended in the Emergency Department is progressively increasing in trend, owing to the rising statistics of motor-vehicle accidents (MVAs) and urban assaults in addition to occupational-related injuries. Prompt and thorough assessment is important for accurate diagnosis and paramount treatment plans. We will be discussing a case of unusual presentation of an orbital floor fracture post-MVA which was treated conservatively based on the clinical assessments during follow-ups, supported by radiological findings. We will also briefly discuss the different radiological modalities available in assessing MFT and late presentation of enophthalmos.
https://ift.tt/2jRE6PO
